Feline Immunodeficiency Virus (FIV) infects an estimated 2.5% of cats in the US, with much higher rates in outdoor and feral populations. The virus has historically been treated as a terminal diagnosis with palliative care only. Morris Animal Foundation's 2025 FIV research program produced two significant findings. First, a clinical trial of GS-441524 (the same antiviral successfully used against FIP, a related coronavirus) showed measurable reduction in FIV viral load and improved immune function in 71% of treated cats over a 12-week course. Second, a long-term behavioral study of FIV-positive indoor cats found median survival from diagnosis of 7.5 years — with many cats dying of unrelated causes, never showing AIDS-stage disease. The virus progresses dramatically slower in cats with stable, low-stress environments and consistent preventive care.
If your cat tests FIV-positive, do not euthanize. FIV-positive indoor cats live long, full lives in the vast majority of cases. The key management factors are: keep them indoors (to prevent secondary infections and to prevent spreading FIV to other cats), maintain regular vet checkups every 6 months rather than annually, and address stress aggressively (stress accelerates immune decline). Discuss GS-441524 with your vet — it is not yet widely approved for FIV but is increasingly available through veterinary compounding pharmacies with promising results.